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Protein kinase B (PKB/Akt) is a pivotal regulator of diverse metabolic, phenotypic, and antiapoptotic cellular controls
and has been shown to be a key player in cancer progression. Here, using fluorescent reporters, we shown in cells that,
contrary to in vitro analyses, 3-phosphoinositide–dependent protein kinase 1 (PDK1) is complexed to its substrate,
PKB. The use of Fo ¨rster resonance energy transfer detected by both frequency domain and two-photon time domain
fluorescence lifetime imaging microscopy has lead to novel in vivo findings. The preactivation complex of PKB and
PDK1 is maintained in an inactive state through a PKB intramolecular interaction between its pleckstrin homology (PH)
and kinase domains, in a ‘‘PH-in’’ conformer. This domain–domain interaction prevents the PKB activation loop from
being phosphorylated by PDK1. The interactive regions for this intramolecular PKB interaction were predicted through
molecular modeling and tested through mutagenesis, supporting the derived model. Physiologically, agonist-induced
phosphorylation of PKB by PDK1 occurs coincident to plasma membrane recruitment, and we further shown here that
this process is associated with a conformational change in PKB at the membrane, producing a ‘‘PH-out’’ conformer and
enabling PDK1 access the activation loop. The active, phosphorylated, ‘‘PH-out’’ conformer can dissociate from the
membrane and retain this conformation to phosphorylate substrates distal to the membrane. These in vivo studies
provide a new model for the mechanism of activation of PKB. This study takes a crucial widely studied regulator
(physiology and pathology) and addresses the fundamental question of the dynamic in vivo behaviour of PKB with a
detailed molecular mechanism. This has important implications not only in extending our understanding of this
oncogenic protein kinase but also in opening up distinct opportunities for therapeutic intervention.
Citation: Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, et al. (2007) Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS
Biol 5(4): e95. doi:10.1371/journal.pbio.0050095
Introduction
A key downstream relay in various growth factors and
hormones is the activation of the serine/threonine protein
kinase (PKB/Akt). PKB activates a plethora of proteins that
are involved in metabolism, proliferation, growth, and
survival [1–3]. Several lines of evidence indicate that the
PKB pathway is involved in human cancer, and in particular,
its overexpression induces malignant transformation and
chemoresistance [2,4,5]. Its activation is thought to proceed
through the recruitment of the protein to membranes via
interaction of its PH domain with the phosphoinositides
produced by phosphoinositide-3-kinase [speciﬁcally PtdIns
(3,4,5)P3 and PtdIns (3,4)P2] [6,7]. The lipid-bound PKB is then
phosphorylated by 3-phosphoinositide–dependent protein
kinase 1 (PDK1), which is also recruited through its PH
domain binding to PtdIns (3,4,5)P3. The PDK1 phosphoryla-
tion, critical for activation, occurs at Thr308 in the activation
T-loop of PKBa [8]. A second phosphorylation within a C-
terminal hydrophobic motif at Ser473 acts in synergy to fully
activate the protein kinase. It is believed that this phosphor-
ylation occurs via the mTor:rictor pathway [9]. Our under-
standing of the mechanism of activation of PKB remains
limited as, unlike other AGC kinases that are substrates for
PDK1 [10], direct in vitro or in vivo interaction of PKB with
PDK1 has not been observed. The current models of PKB
activation only speculate, based on the regulation of other
AGC kinases, how PKB may change its conformation to
interact with PtdIns at the plasma membrane and thereafter
be activated by PDK1. The functionally independent behav-
iour of the PH and kinase domains of PKB is well
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rately [6,7,11–13]. In isolation, the PH domain retains
intrinsic lipid binding properties and, similarly, the kinase
domain retains function [14,15]. The kinase domain is well
understood structurally with respect to its inactive and active
conformers [12,13]. However, the more complex interactions
between the PH and kinase domains have not succumbed to
direct structural analysis and remain to be elucidated. The
recent advent of an in vivo probe to monitor PKB conforma-
tional changes in conjunction with molecular modeling has
permitted analysis of the mechanism by which these two
domains interact and how PKB changes conformation in
relation to its activation by PDK1. We have addressed the
possible molecular mechanisms involved in the conforma-
tional dynamics of PKB and dissected its activation in intact
cells. This has important implications not only in extending
our understanding of this critical regulator but also in
opening distinct opportunities for therapeutic intervention.
Results
PDK1 Precomplexes with Its Substrate PKB in the
Cytoplasm
It has been assumed that upon activation of various growth
factor pathways, PDK1 and PKB uniquely colocalise at the
plasma membrane, permitting PDK1 to phosphorylate PKB.
To assess in single cells the dynamic relationship between
PKBa and PDK1, Fo ¨rster resonance energy transfer (FRET)
was exploited. Two fusion proteins were generated by
genetically encoding enhanced green ﬂuorescent protein
(EGFP) (donor) at the N terminus of PDK1 and monomeric
RFP (acceptor) at the N terminus of PKBa. NIH3T3 cells were
transfected with the expression vectors for GFP-PDK1 and
RFP-PKB, and the expressed proteins behaviours were
followed upon stimulation of the platelet-derived growth
factor (PDGF) receptor pathway (note that the levels of
expression were the minimum required for data acquisition).
For optimum spatial resolution, FRET was monitored by two-
photon ﬂuorescence lifetime imaging microscopy (FLIM).
Resonance energy transfer was detected by the decrease in
the donor lifetime in the presence of the acceptor. The
variations in lifetime are presented by lifetime distributions
curves and mean FRET efﬁciency. Coexpression of RFP-PKB
with GFP-PDK1 in NIH3T3 cells (Figure 1A) induced a
decrease in the lifetime of GFP-PDK1. The decrease in the
donor lifetime is quantitatively presented by the lifetime
distribution curves. The blue curve is the GFP-PDK1 when
expressed alone, and the green curve is when it is expressed
with RFP-PKB (acceptor). From this reduction in lifetime, we
deduced that, at steady state, GFP-PDK1 and RFP-PKB
interact in the cytoplasm. The cytoplasmic mean FRET
efﬁciency presented as box and whiskers plots is 2.5 (Figure
1C). Upon PDGF stimulation, both PKB and PDK1 trans-
located to the plasma membrane, and a further decrease in
the average lifetime was detected (orange curve). The trans-
location of RFP-PKB to the plasma membrane is clearly
shown in Figure S6. The separation of the lifetime distribu-
tions at the plasma membrane versus the cytoplasm (red
curve: plasma membrane; light green curve: cytoplasm)
showed that at the plasma membrane, the mean FRET
efﬁciency is 7.1, and in the cytoplasm, it is 4.9 (Figure 1C).
These results indicated that PDK1 and PKB interacted under
basal conditions and that the stimulation of the PDGF
receptor pathway promoted an enrichment of the PKB–
PDK1 complex at the plasma membrane. This intermolecular
interaction was also demonstrated by frequency domain
FLIM (Figure S1). This behaviour indicates that in the
cytoplasm, the PKB–PDK1 complex is at equilibrium deter-
mined by the bulk phase concentrations. Upon stimulation,
the local concentration of both proteins is enhanced at the
plasma membrane, whereby the equilibrium is shifted toward
the formation of the PKB–PDK1 complex.
To verify that the PKB–PDK1 interaction was due to
docking and not purely concentration effects in the
cytoplasm due to transfection, GFP-PKB alone or together
with RFP-PKB was expressed in NIH3T3 cells (Figure 1B). The
lifetimes from cells with expression levels of donor (GFP-
PKB) and acceptor (RFP-PKB), comparable to those of GFP-
PDK1 and RFP-PKB, were identiﬁed. Despite the colocalisa-
tion of GFP-PKB and RFP-PKB in the cytoplasm and the
corecruitment of both PKBs at the plasma membrane, upon
activation, the FRET efﬁciency did not change. This is clearly
illustrated by the complete lack of lifetime variation (Figure
1B and 1C). These data indicated that PDK1 and PKB were
docking in the cytoplasm and at the plasma membrane under
steady state and stimulated conditions.
To further investigate whether the docking was PtdIns
(3,4,5)P3 dependent, cells were pretreated with the phospha-
tidylinositol 3-kinase inhibitor LY294002 prior to PDGF
stimulation. Figure 1D shows that with LY294002, the
translocation of PKB and PDK1 is prevented. However, a
cytoplasmic FRET efﬁciency of 3.4, similar to basal con-
ditions, was still observed (Figure 1E). The PDGF-induced
phosphorylation of Thr308 and Ser473 was reduced on
pretreatment with LY294002 (Figure S2E). This indicated
that the recruitment of the PKB–PDK1 complex to the
plasma membrane was dependent on PtdIns (3,4,5)P3 pro-
duction, while the docking of PKB to PDK1 in the cytoplasm
was PtdIns (3,4,5)P3 independent. To assess the role of PtdIns
(3,4,5)P3 in an inhibitor-independent manner, PKB and PDK1
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Author Summary
Regulation of intracellular signaling depends on the precise
operation of molecular switches such as kinases and phosphatases.
Disruption of their activities leads to inappropriate cellular
proliferation, growth, and survival. Protein kinase B (PKB) is a critical
kinase that regulates events downstream of growth factor receptors.
It is also involved in human cancer, where its overexpression induces
malignant transformation. We studied the molecular mechanisms of
PKB’s interaction with its upstream regulator, 3-phosphoinositide–
dependent protein kinase 1 (PDK1). By using a fluorescent probe, we
monitored the conformational changes of PKB in cells using Fo ¨rster
resonance energy transfer detected by fluorescence lifetime
imaging microscopy. Applying this approach, we show that PKB
and PDK1 are found as complexes in the cytoplasm. Despite this
proximity to its regulator, we show that PKB remains inactive
through an intramolecular interaction of its pleckstrin homology
(PH) domain and kinase domain. We refer to this inactive state as the
‘‘PH-in’’ conformer. Following growth factor activation, PKB changes
conformation to the ‘‘PH-out’’ conformer and is phosphorylated by
PDK1. The active ‘‘PH-out’’ conformer dissociates from the plasma
membrane to phosphorylate downstream proteins. Our in vivo
studies provide a new model for the mechanism of PKB.PH domain mutants (mutants that do not efﬁciently bind to
phosphoinositide lipids: PDK1 RRR and PKB R25C [16,17])
were used to determine their inﬂuence on interaction with
their wild-type binding partners. Cells were cotransfected
with GFP-PDK1/RFP-PKB R25C or GFP-PDK1 RRR/RFP-PKB.
Under basal conditions, both wild-type proteins interacted
with their mutant partner (Figure S3A and S3B). However,
upon activation, the PH mutants did not translocate to the
plasma membrane and a change in FRET efﬁciency was not
detected (Figure S3C). It is concluded that complex formation
in the cytosol is independent of lipid binding.
PDK1 docks with phosphorylated/acidic hydrophobic mo-
tifs at the C termini of some AGC kinases. This is affected
through a PDK1 interacting fragment domain (PIF pocket)
and additionally through a phosphate-binding site within the
upper lobe of the PDK1 kinase domain. PDK1 mutants
defective in these interactions, namely the L155E mutant in
the PIF pocket and the R131A mutant in the phosphate-
binding pocket, still interacted with PKB in the cytoplasm or
on PDGF stimulation at the plasma membrane (Figure S4A
and S4B). Moreover, the PKB mutant that is not phosphory-
lated in response to agonists, T308A/S473A (Figure S4C), also
retained binding capacity, conﬁrming independently that
PKB Ser473 phosphorylation was not required for docking
into PDK19s phosphate-binding pocket. Therefore, the
interaction of PKB and PDK1 is independent of the PIF
Figure 1. PDK1 Interacts with PKB in a Phosphatidylinositol 3-Kinase–Dependent Manner at the Membrane and in a Phosphoinositide-Independent
Manner in the Cytoplasm
(A) NIH3T3 cells were transfected with GFP-PDK1 alone or with RFP-PKB. The lifetimes are presented in pseudo-colour scale ranging from 2.0 to 2.7 ns.
The graph presents the lifetime distributions of the cells for the following conditions: GFP-PDK1 (blue), GFP-PDK1 with RFP-PKB prior (green) and upon
PDGF stimulation (orange). The red and the light green lines indicate the lifetime distributions of the plasma membrane and cytoplasm pixels,
respectively, after separation of the compartmental pixels (see decomposition).
(B) NIH3T3 cells were transfected either with GFP-PKB alone or together with RFP-PKB. The FRET efficiency variation is statistically insignificant.
(C) The statistical analysis of experiments in A and B are presented as box and whiskers plots (see Supporting Information). The FRET efficiency was
calculated for at least ten cells per condition for the cytoplasmic (Cyto) and plasma membrane (PM) components, as indicated. The first column shows
the variation of the donor lifetime (blue) centred at zero. The dispersion is less than 61%. The FRET efficiency of GFP-PDK1 þ RFP-PKB condition is
presented before (green boxes) and after (red boxes) PDGF stimulation. The FRET efficiency of the control GFP-PKBþRFP-PKB upon PDGF is presented
by the two last boxes. The mean value of the FRET efficiency is indicated on top of each box. The highly significant FRET efficiency variations at (PM), for
experiment A, is indicated by a p-value of 0.002 (see Supporting Information).
(D) Similar experiment as in (A) was performed but cells were first pretreated for 20 min with LY294002. The graph shows the superposition of the
lifetime distributions of coexpressed GFP-PDK1 and RFP-PKB pretreated with LY294002 alone (green line) or pretreated with LY294002 before PDGF
stimulation (dashed green line). Control GFP-PDK1 lifetime distribution is shown in blue.
(E) The FRET efficiency between LY294002- and LY294002 þ PDGF–treated cells do not vary significantly (p ¼ 0.8).
doi:10.1371/journal.pbio.0050095.g001
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In Vivo PKB Molecular Mechanismand the phosphate-binding pockets and does not require
phosphorylation of Thr308 or Ser473 (Figure S4D). In line
with this observation, it has also been shown by using knock-
in mutants of PDK1 that the PIF pocket and the phosphate-
binding pocket of PDK1 were not implicated in the activation
of PKB [18,19]. Therefore, the interaction in the cytoplasm
occurs via mechanisms that are distinct from those of other
AGC kinases.
Since these kinases interacted in the cytoplasm, it was of
interest to determine why PKB was not constitutively
phosphorylated by the associated PDK1 in the basal state.
One of the mechanisms that regulate the basal levels of
Ser473 is the dephosphorylation of this residue by a serine/
threonine protein phosphatase, PP2A, implicated in the
downregulation of PKB activation [20]. It was postulated that
dephosphorylation may dominate the cytoplasmic phosphor-
ylation of PKB. To test this hypothesis, PP2A activity was
blocked by treating cells with okadaic acid. The time-
dependent increase of RFP-PKB Ser473 phosphorylation
upon treatment indicated that in the absence of PP2A,
phosphorylation of Ser473 was enhanced, showing that in
NIH3T3 cells PP2A regulates Ser473 phosphorylation in the
cytoplasm (Figure S2A). The okadaic acid–insensitive phos-
phatase PHLPP [21] cannot therefore regulate the basal
phosphorylation process. Unlike Ser473, the okadaic acid
stimulation of Thr308 was modest. It was possible that the
‘‘basal state’’ phosphorylation induced by okadaic acid
occurred via a transient PtdIns (3,4,5)P3–associated form.
To investigate this, we exploited the nonbinding PH domain
mutant of PKB (RFP-PKB R25C). The okadaic acid–induced
phosphorylation of Ser473 and Thr308 did not differ
signiﬁcantly from that of wild-type PKB, whereas the PDGF-
induced phosphorylation of RFP-PKB R25C was signiﬁcantly
reduced (Figure S2B). These data indicated that the okadaic
acid–induced phosphorylations occurred in the cytoplasm. In
RFP-PKB–transfected cells, the okadaic acid–induced Ser473
phosphorylation was at the same level as the Ser473
phosphorylation induced by PDGF (Figure S2A, densitom-
etry). However, in the case of phospho-Thr308, the okadaic
acid signal was reduced compared to phosphorylation
triggered by PDGF stimulation (Figure S2A, densitometry).
The reduced phosphorylation of Thr308 led to the hypothesis
that Thr308 was inaccessible in the cytoplasmic PDK1
complex due to PH domain steric hindrance. If this
hypothesis is correct, then the removal of the PH domain
should alter the kinetics of Thr308 phosphorylation in
response to okadaic acid. Thr308 phosphorylation of the
deletion mutant RFP-DPH PKB was more extensive than the
wild-type PKB (Figure S2C). This provided evidence that, in
the cytoplasm, Thr308 was not fully accessible to PDK1 and
hence could not be phosphorylated.
To verify that in the RFP-DPH-PKB mutant Thr308
phosphorylation was due toP D K 1 ,N I H 3 T 3c e l l sw e r e
cotransfected with RFP-DPH PKB and GFP-PDK1 wild-type
or the PH domain mutant GFP-PDK1 RRR (Figure S2D). In all
cases, a prominent phosphorylation of Thr308 independent
of PDGF was detected. Therefore, it is established that when
the PKB PH domain is absent, Thr308 could be phosphory-
lated by PDK1 within the cytosolic complex. Thus, for
maintenance of PKB in a Thr308-dephosphorylated state
under basal conditions, its PH and kinase domains are
predicted to interact to obscure Thr308 accessibility.
PKB PH and Catalytic Domains Interact in the PKB
Inactive State
To test the above hypothesis and determine the possible
interactive sites of the PH and kinase domains, molecular
modeling was exploited. The calculations of lipophilicity
potentials of the PH and kinase domains resulted in ﬁnding
two isolated hydrophobic patches that were located on the
kinase domain (Figure 2A, in blue). On the PH domain, four
small hydrophobic patches were found (Figure 2A, in cyan)
and were located on the same side of the protein. To test the
validity of this molecular model, the electrostatic potential
maps of each domain were calculated. The complementarity
observed between the positive (red) and negative (blue) lobes
for the two domains (Figure 2B) was almost perfect. The
upper positive lobe of the PH domain corresponded to the
upper negative lobe of the kinase domain, and reciprocally,
the negative lobe on the PH domain corresponded to a
positive lobe on the kinase domain. Figure 2C shows the
complementarity between the acidic and the basic residues in
the kinase and PH domains of PKB. The yellow arrows
indicate the pair of complementary residues on each domain.
The ﬁt of the hydrophobic interactions predicts that the
Trp80 on the PH domain, at the extremity of the variable
loop 3, inserts inside a deep cleft in the kinase domain
around residues Lys297, Glu298, and Glu314 (Figure 2D).
Furthermore, the crystal structure of the isolated PKB PH
domain showed that Trp80 may have an important role in the
interaction of the two domains of PKB [7].
From the complementarity of the basic and acidic residues
located around Trp80 in the PH and kinase domains, it was
envisaged that mutations of these regions would disrupt the
Figure 2. PKB PH and Catalytic Domains Interact in the PKB Inactive State
(A) The solvent-accessible surface of the domains are shown in green (PH) and in yellow (kinase) and the hydrophobic patches are indicated. The IP4
binding site is in magenta (located to the rear of PH domain) and the ATP active site is in red.
(B) The electrostatic potential maps of PKB PH and kinase domains are calculated in the complexed form, based on crystal structures of PKBa PH
domain. A strong complementarity between the positive and negative lobes of the PH and kinase domains is seen.
(C) Acidic (red), basic (blue), and polar (green) residues are presented here. The Trp80 is shown in purple and Arg25 is shown in light blue. The yellow
arrows show the complementarity between the acidic and basic residues in each domain. The orange arrow shows the docking site of Trp80 in the
kinase domain cleft.
(D) The model of complexed PKBa PH domain (yellow) and the rebuilt catalytic domain model (green) is based on the hydrophobicity in an aqueous
environment. To visualise the binding site of the lipid head group in the complex, IP4 is represented as CPK (Corey-Pauling-Koltun) orange spheres. Note
that IP4 cannot be positioned unless the PH and kinase domains are separated.
(E) NIH3T3 cells were transfected either with GFP-PKB or GFP-PKB-RFP (WT) or mutant (EE). The lifetimes are in pseudo-colour scale ranging from 2.30 to
2.67 ns. The graph shows the lifetime distributions: GFP-PKB (blue), GFP-PKB-RFP WT (green), and EE (red). The statistical analysis shows the highly
significant variation of FRET efficiency between WT and EE (p ¼ 0.004).
(F) Expression of GFP-PKB-RFP and phosphorylation on Thr308 and Ser473 sites is determined by Western blot using total protein (WB Akt) or
phosphospecific antibodies as indicated.
doi:10.1371/journal.pbio.0050095.g002
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in the kinase domain is indicated by an orange arrow (Figure
2C). The two polar residues Gln79 and Thr82, surrounding
Trp80, were mutated to Glu. These mutations were predicted
to result in disruption of the two domains since the acidic
residues repulse one another instead of the polar residues of
the PH domain interacting with acidic residues of the kinase
domain.
To monitor and validate in situ our hypothesis on the
docking sites of PKB-PH and kinase domains and speciﬁcally
the Gln79Glu/Thr82Glu mutant (PKB-EE mutant), a PKB
reporter was constructed. Full-length PKBa with EGFP on the
N terminus and monomeric red ﬂuorescent protein (mRFP)
on the C terminus (GFP-PKB-RFP) was genetically encoded.
Variations in PKB conformation were monitored by changes
in FRET efﬁciency. NIH3T3 cells were transfected with PKB
tagged only with GFP to use as the reference lifetime (GFP-
PKB) or with the double-tagged GFP-PKB-RFP reporter
(Figure 2E). Under basal conditions, a change in GFP lifetime
and FRET efﬁciency in the GFP-PKB-RFP reporter construct
was monitored (Figure 2E, box and whiskers plots). The
dynamics of the double-tagged reporter is shown in Figure
S5. It is of note that double-tagged PKB can be phosphory-
lated on both Thr308 and Ser473 (Figure 2F). The FRET
signal under basal conditions was indicative of the close
proximity of the two domains in the inactive conformer of
Figure 3. Phosphoinositide-Dependent Change in PKB Conformation at the Plasma Membrane
(A) NIH3T3 cells were transfected either with GFP-PKB or GFP-PKB-RFP. Upon PDGF treatment, GFP-PKB-RFP translocated to the plasma membrane and
changed in conformation. The lifetimes are represented in pseudo-colour scale ranging from 2.20 to 2.63 ns. As indicated, the cells were pretreated for
20 min with LY294002 before PDGF stimulation. LY294002 prevented the translocation of GFP-PKB-RFP to the plasma membrane and its change in
conformation but did not affect the FRET efficiency in the cytoplasm.
(B) The lifetime distributions are shown on the graphs: GFP-PKB control (blue), GFP-PKB-RFP (green), and GFP-PKB-RFP upon PDGF (orange) and treated
with LY294002 before PDGF stimulation (dashed green). The separation of the lifetime pixels at the plasma membrane (red) and cytoplasm (light green)
is shown for GFP-PKB-RFP upon PDGF stimulation.
(C) The statistical analysis presented as box and whiskers plots shows the extremely significant change in FRET efficiency (p ¼0.0006) of GFP-PKB-RFP
before and upon PDGF stimulation at the plasma membrane (PM) and the loss of FRET change when pretreated with LY294002.
doi:10.1371/journal.pbio.0050095.g003
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(GFP-PKB EE-RFP), a further decrease in the lifetime of the
reporter (red lifetime distribution curve) was detected and
the FRET efﬁciency signiﬁcantly increased to 5.2 (Figure 2E,
box and whiskers plots). As predicted from molecular model,
the double-Glu mutation perturbed the juxtaposition of the
PH and kinase domains as reﬂected in this altered N-terminal
to C-terminal FRET (Figure 2E).
Phosphoinositide-Dependent PKB Conformation Change
at the Plasma Membrane
The molecular model implied that a close interaction
between the PH and kinase domains was formed as predicted
from the complementary surfaces and shown by the
extremely signiﬁcant variations in FRET efﬁciency between
wild-type and mutant PKB. This inactive conformer will be
referred to as the ‘‘PH-in’’ conformation. In order for PDK1
to access Thr308, it was predicted that the PH domain alters
its association with the kinase domain on binding to lipids,
i.e., a ‘‘PH-out’’ conformation.
To test this hypothesis, the GFP-PKB-RFP reporter was
expressed in NIH3T3 cells and its behaviour was monitored
upon stimulation with PDGF. Figure 3A illustrates that PDGF
induced a change in the conformation of PKB concomitant
with its translocation to the plasma membrane. The lifetime
distribution curves demonstrated the changes in lifetime
Figure 4. PKB Conformation Dynamics Revealed in Live Cells
(A) A series of two-photon FLIM images of a GFP-PKB-RFP–transfected NIH3T3 cell were acquired over a period of 20 min (every 54 s). The top panels
represent intensity images of the donor GFP chromophore in the transfected cell after two photon excitation. The bottom panels represent the
calculated lifetime maps of GFP-PKB-RFP over time. After treatment with 60 ng/ml PDGF, cells were observed under the microscope. Acquisition took
place once the construct had translocated to the membrane. The lifetimes are represented in pseudo-colour scale ranging from 2.27 to 2.64 ns.
(B) The variations of fluorescence intensity at the plasma membrane (red squares) in the cytoplasm (blue circles) and in the nucleus (black triangles)
were detected over time.
(C) The time-course graph presents the enrichment in short lifetime pixels of six different experiments. Each coloured triangle presents a cell. The
enrichment of short lifetime pixels is calculated as described in Supporting Information.
(D) Under basal conditions, PKB and PDK1 form a complex in the cytoplasm where the associated and dissociated forms are in dynamic equilibrium.
Four possible equilibrium states of PKB–PDK1 complex in its inactive conformation are represented. In the PKB inactive conformation, PKB PH and
kinase domains interact, noted as ‘‘PH-in.’’ The equilibrium between a ‘‘tighter’’ and a ‘‘looser’’ interaction of PKB PH with its kinase domain is also
represented. Upon PDGF stimulation, the PKB–PDK1 complex is recruited to the plasma membrane due to interaction with phosphoinositides (in red).
The equilibrium of PKB–PDK1 interaction is shifted toward the associated form, a process compromised by LY294002. The interaction of PKB PH domain
with the lipids induces a change in conformation of PKB, noted as ‘‘PH-out.’’ In this conformation, Thr308 becomes accessible to PDK1 (the
phosphorylation sites are represented by yellow circles). After Ser473 phosphorylation and loading of ATP, PKB dissociates from the plasma membrane
in its active conformation to return to the cytoplasm and the nucleus. PKB re-adopts an inactive conformation upon dephosphorylation of its Thr308
and Ser473 sites.
doi:10.1371/journal.pbio.0050095.g004
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In Vivo PKB Molecular Mechanism(Figure 3B), as did the FRET efﬁciencies (Figure 3C). By
separating the plasma membrane pixels from those of the
cytoplasm, the mean FRET efﬁciency of each compartment
was calculated to be 7.0 and 4.8, respectively (Figure 3C, p ¼
0.0006). The cytoplasmic FRET efﬁciency in PDGF-treated
cells in this acute response was similar to basal level FRET
efﬁciency (Figure 3C), indicating that the ‘‘PH-in’’ conformer,
unless recruited to the plasma membrane, remained un-
changed. Pretreatment with LY294002 inhibited the con-
formational change in wild-type PKB as seen by the overlap
of the distribution curves (Figure 3B, green and dashed green
lines). Similarly, the nonbinding PH domain mutant of PKB
(RFP-PKB R25C-RFP) was not recruited to the plasma
membrane and did not change conformation upon stimula-
tion with PDGF (unpublished data). In conclusion, the
association of the PH domain with phosphoinositides at the
plasma membrane induced a change in PKB conformation by
stabilising the ‘‘PH-out’’ conformer and so permitting Thr308
phosphorylation.
PKB Conformation Dynamics Revealed in Live Cells
It has been suggested that PKB in its active state dissociates
from the membrane and can phosphorylate soluble targets
[22]. However, the ‘‘PH-in’’ conformer may be obscuring its
substrate-binding pocket so that PKB’s downstream targets
will not have access to it. Thus, we speculated that upon
dissociation from the plasma membrane, phosphorylated
PKB would remain in a ‘‘PH-out’’ conformer where it can
phosphorylate cytosolic substrates. To follow the dynamics of
the ‘‘PH-out’’ conformer on dissociation from the plasma
membrane, the behaviour of the PKB conformation reporter
(GFP-PKB-RFP) was assessed in live cells (Figure 4). Cells were
transfected with the reporter, and upon stimulation with
PDGF, images were acquired every 54 s for up to 20 min
(Figure 4A). The intensity images and the quantiﬁcation of
ﬂuorescence intensity illustrated a replenishment of the
cytoplasmic ﬂuorescence, which coincided with a decrease
in the ﬂuorescence intensity at the plasma membrane (Figure
4B) upon recruitment of PKB. The lifetime maps show that
the translocated PKB changed conformation, and over time,
the populations of the shorter lifetime pixels were augmented
in the cytoplasm and the nucleus (Figure 4A). The quantiﬁ-
cation of these lifetime variations in six different experiments
demonstrated that the mean FRET efﬁciency, upon stimula-
tion, increased gradually over time (Figure 4C). This indicated
that during the 20 min of ﬁlming, the de novo PDGF-
activated ‘‘PH-out’’ PKB conformer dissociated from the
membrane and became distributed in the cytoplasm and the
nucleus.
Discussion
Assembling these observations produces a new molecular
model for PKB activation dynamics (Figure 4D). Prior to
stimulation, PKB and PDK1 form a complex in the cytoplasm
that is in constant equilibrium between the associated and
dissociated forms. Under basal conditions, PKB is maintained
in its inactive form by the interaction of its PH and kinase
domains (‘‘PH-in’’). The ‘‘PH-in’’ conformation is responsible
for preventing the phosphorylation of Thr308 by the
associated PDK1. The cytoplasmic and membrane interac-
tions of PKB and PDK1 are similar in nature. These proteins
are in dynamic equilibrium, and it is their corecruitment that
concentrates them at the plasma membrane to shift the
equilibrium state and form more complex at this location.
PKB PH domain interaction with phosphoinositides and its
concomitant change in conformation (‘‘PH-out’’) form the
critical step that allows the associated, corecruited PDK1 to
phosphorylate Thr308.
In live cells, the dynamics of PKB activation shows that it
remains in the ‘‘PH-out’’ conformer upon dissociation from
the plasma membrane. Active PKB accumulates in both the
cytoplasm and the nucleus. This observation suggests that
the phosphorylated kinase domain has a lower afﬁnity for
the PH domain, thereby sustaining the ‘‘PH-out’’ conformer,
whereas the dephosphorylated kinase domain has a higher
afﬁnity for the PH domain. This higher afﬁnity for the PH
domain, in the inactive form of PKB, maintains the ‘‘PH-in’’
conformer. The ‘‘PH-out’’ conformer probably sustains its
activity until phosphatases render it inactive; once inacti-
vated by dephosphorylation, the ‘‘PH-out’’ conformer
returns to the ‘‘PH-in’’ conformation. Aside from providing
a rationale for observations related to the mechanism of
PKB activation, this detailed model makes interesting
predictions regarding the potential sites for inﬂuencing
PKB and its activation. Speciﬁcally, it is predicted that
compounds inﬂuencing the ‘‘PH-in’’ versus ‘‘PH-out’’ con-
formers will inﬂuence the activation state of PKB. This may
have implications both in cancer where PKB is aberrantly
activated and in diabetes where transient PKB activation
might be insulinomimetic.
Materials and Methods
Materials and antibodies. Mowiol 4–88, LY294002 in solution,
okadaic acid, and sodium salt were from Calbiochem (Merck KGaA,
http://www.merck.de). Human PDGF was from R&D Systems (http://
www.rndsystems.com). Cyan 3 dye was from Amersham Biosciences
UK (http://www.amersham.com). Phospho-Akt Thr308 and Ser473 as
well as pan Akt were from Cell Signaling (New England BioLabs UK,
http://www.neb.com). Anti-HA and -GFP antibodies were in-house
monoclonal antibodies. Sodium borohydride (NaBH4) and other
chemicals were from Sigma-Aldrich Company Ltd. (http://www.
sigmaaldrich.com). Poly-L-lysine–coated glass coverslips were from
Marathon Laboratory Supplies (London, United Kingdom).
Fusion constructs design and direct site mutagenesis. pRSET B-
mRFP was kindly provided by Dr Roger Tsien (University of
California). The construct pCMV5-EGFP-PDK1 (human PDK1) was
described previously [23].
To create mRFP-PKB, mRFP was PCR ampliﬁed from pRSET B-
mRFP with the following oligos: mRFP sense: agagaattcgccgccac-
catggcctcctccgaggacgtcatcaaggagttcatgcgc, and mRFP antisense: atc-
gaattctgcaccggtggagtggcggccctcggcgcgctcgtactgttcc. PCR-ampliﬁed
mRFP was then subcloned into the murine AKT1 (described
elsewhere [24]) in an EcoRI site in N terminus of HA-PKB. An extra
EcoRI site (in the vector) C terminus of PKB was eliminated by
mutagenesis prior to the subcloning of RFP using the following
primers: EcoRI less-sense: gccacgctgtcctccgcaattcgagctctagaggatcccgg,
and EcoRI less-antisense: ccgggatcctctagagctc gaattgcggag ga-
cagcgtggc.
mRFP-DPH-PKB was made by PCR-amplifying mRFP and put in
instead of EGFP using the ﬂanking restriction sites NheI-BglII in
pEGFP-DPH-PKB vector (previously described [25]). The oligo used
for the PCR ampliﬁcation of mRFP, kindly provided by Dr Johanna
Durgan (CRUK, London, England), are NheI sense: aatatagctag-
catggcctcctccgaggacg, and BglII antisense: atataaagatcttgcgccggtg-
gagtggcggccctc.
The different mutants of PKB and PDK1 were obtained by direct
site mutagenesis using the Quick Change mutagenesis kit from
Stratagene (Stratagene Europe, http://www.stratagene.com). The oli-
gonucleotides sequence used for each mutant is as follows: PKB-R25C
sense: caagacctggcggccatgctacttcctcctcaagaatgatggcacc, PKB-R25C
antisense: ggtgccatcattcttgaggaggaagtagcatggccgccaggtcttg, PKB-
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S473A antisense: cgtgctgctggccgagtaggcgaactgggggaagtggggcctgcg,
PKB-T308A sense: gacggtgccaccatgaaggccttttgcggcacacctgagtacctg,
PKB-T308A antisense: caggtactcaggtgtgccgcaaaaggccttcatggtgg-
caccgtc, PDK1-RRR-LLL sense: gcggaagggtttatttgcactactacta-
cagctgttgctcacagaagg, PDK1-RRR-LLL antisense:
ccttctgtgagcaacagctgtagtagtagtgcaaataaacccttccgc, PKB-EE sense:
cctttatcatccgctgcctggagtggaccgaagtcattgagcgcaccttc, PKB-EE anti-
sense: gaaggtgcgctcaatgacttcggtccactcc aggcagcggatgataaagg, PDK1-
L155E sense: catttcaggacgacgagaaggagtatttcggccttagttatgcc, PDK1-
L155E antisense: ggcataactaaggccgaaatactccttctcgtcgtcctgaaatg,
PDK1-R131A sense: ggtcccctatgtaaccagagaggcggatgtcatgtcgcgcctgg,
and PDK1-R131A antisense: ccaggcgcgacatgacatccgcctctctggttaca-
taggggacc.
pEGFP-HA-Akt construct was described previously (murine AKT1
[14]; to simplify, we called this construct GFP-PKB).
GFP-PKB-RFP was created by putting PCR-ampliﬁed mRFP
(EcoRI-XbaI) instead of YFP in the vector pCDNA3-GFP-PKB-YFP
(described previously [26]), using the following oligos: mRFP-Ct sense:
agagaattcgcctcctccgaggacgtcatcaaggagttcatgcgcttcaagg, and mRFP-Ct
antisense: atctctagattatgcaccggtggagtggcggccctcggcgcgctcg tactgttcc.
Note that an extra XbaI site had to be removed by QuickChange in
the pCDNA3-GFP-PKB-YFP construct before the subcloning of
mRFP (EcoRI-XbaI).
Cell culture and transfections. NIH3T3 cells from ATCC (http://
www.atcc.com) were maintained in DMEM 10% donor calf serum and
seeded at 150,000 in a well of a six-well plate or in a MatTek dish. The
transfection was done with 2 lg of DNA of the different constructs (2
þ 2 lg for cotransfections) using LipofectAMINE/PLUS reagent
(GIBCO BRL, http://www.invitrogen.com) in OptiMEM medium
(GIBCO BRL) as recommended by the manufacturer. The cells were
left for 3 h in the transfection mix and then the medium was removed
and replaced with DMEM 10% donor calf serum. The experiments
were performed 24 or 48 h after transfection.
Lysis conditions and Western blot analysis. After stimulation or
treatment as indicated, the cells were lysed for 15 min on ice in lysis
buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 100 mM NaF, 10 mM
Na4P2O7, and 10 mM EDTA supplemented with Complete protease
inhibitor cocktail tablet [Roche, http://www.roche.com]). To terminate
the reaction, 43 SDS sample buffer (125 mM Tris-HCl [pH 6.8], 6%
SDS, 20% glycerol, 0.02% bromophenol blue supplemented with
10% b-mercaptoethanol) was added, and the samples were boiled for
5 min. The proteins were separated on a 10% SDS-PAGE gel. The gels
were then transferred onto PVDF membrane (Immobilon P; Milli-
pore, http://www.millipore.com), incubated in blocking buffer TBS-T
(10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.05% Tween-20)
supplemented with 3% BSA for 1 h, washed in TBS-T/1% milk for
1 h, and incubated with the different antibodies phospho-Akt
(Thr308) antibody (rabbit polyclonal from Cell Signaling, http://
www.cellsignal.com) or phospho-Akt (Ser473) (rabbit polyclonal
antibody raised against the C-terminus phosphopeptide HFPQFpSY-
SASS of Akt1) at 1:1,000 for 2 to 3 h in TBS-T/3% BSA. Anti-GFP
(mouse monoclonal antibody, CR-UK) was used at 1:5,000 for 1 h. The
secondary HRP-antibodies were used at 1:5,000 in TBS-0.2% Tween-
20 in 5% milk for 1 h. Western blots were revealed by incubation with
ECL (Amersham Biosciences). Density analysis of bands was done with
NIH ImageJ 1.33u (National Institutes of Health, http://rsb.info.nih.
gov/ij). The analysis was performed by substracting the background of
the autoradiography. The intensity of the bands was normalised to
the total amount of protein, and the relative variations were plotted.
FRET by two-photon FLIM. NIH3T3 cells were seeded at 150,000
on 30-mm glass-bottom tissue culture dishes (MatTek) and trans-
fected as described above. At 24 h after transfection, the cells were
treated in DMEM containing 10% donor calf serum. The cells were
washed twice with PBS and then ﬁxed in 4% paraformaldehyde in
PBS for 10 min. The dishes were washed twice with PBS and then 2 ml
of PBS supplemented with 2.5% (w/v) 1,4-diazabicyclo-[2.2.2]-octane
(DABCO) as an antifade was added to the dishes. The images were
acquired straightaway or stored at 4 8C.
For live experiments, the cells were seeded and transfected as
described above. They were treated with 60 ng/ml PDGF in the same
medium, and the lifetime was measured every 54 s with two-photon
FLIM for 20 min. The live experiments were repeated six times to
verify reproducibility.
Details about the method to detect FRET by time domain FLIM
can be found elsewhere [27]. All the images were acquired on a
modiﬁed TE 2000-E inverted microscope (Nikon Ltd., http://www.
nikon.co.uk). The ﬂuorescence lifetime measurements were obtained
using an SPC 830 time-correlated single photon counting (TCSPC)
electronic card (Becker and Hickl, http://www.Becker-Hickl.de) in the
reverse stop-start mode. A mode-locked tuneable Ti:sapphire laser
(Mira 900; Coherent, http://www.coherentinc.com) pumped by a solid-
state diode laser (Verdi; Coherent) was used. For two-photon
excitation of EGFP, the laser was tuned at 890 nm and pumped at 6
W. The Ti:sapphire laser generates 125-fs pulses with a repetition rate
of 76.26 MHz and an average power output of 450 mW. The laser
beam was focused with a 340 oil immersion objective lens (1.3 NA,
Plan-Fluor; Nikon Ltd.). The ﬂuorescence was detected through the
same objective in a descanned conﬁguration and detected with a fast
photomultiplier (Hamamatsu 7400, Hamamatsu, http://www.
hamamatsu.com) after ﬁltering with a bandpass ﬁlter (510 6 10 nm,
Chroma Technology Corp, http://www.chroma.com).
Acquisition parameters. The acquisition parameters were adjusted
to avoid photobleaching [28] and to detect enough photons such that
the signal-to-noise ratio was high enough for data analysis. The power
of the laser beam was decreased to 9 mW with a neutral optical
density ﬁlter. The acquisition time was maintained at 300 s for less-
intense cells but could be reduced to 30 s for brighter ones. A
dwelling time of 17 ls per pixel with a resolution of 2563256 pixels
was used. Photobleaching was evaluated by comparing the photon
count upon time, maintaining the photobleached fraction of EGFP
inferior to 2% in all the acquisitions. Depending on the ﬂuorescence
intensity of the cells, the maximum photon count of the intensity
decay was obtained from 100 to 1,000 counts after a spatial binning of
11 3 11 pixels. The binning was maintained constant throughout all
experiments. The count rate frequency was below 10
5 photons/s to
avoid any pulse pile-up. Epiﬂuorescence intensity images of both
EGFP and mRFP were acquired with the mercury lamp source of the
TE 2000-E microscope and the ﬂuorescence detected by a cooled
CCD camera (Hamamatsu ORCA-ER). The cubes set in the TE 2000-E
microscope turret were FITC (Nikon Ltd.) for EGFP and G-2A (Nikon
Ltd.) for mRFP. No bleed-through was detected.
Data analysis. The analyses were performed using in-house
software developed by the Advanced Technology Development
Group at the Gray Cancer Institute.
FRET measurements were based on the reduction of the
ﬂuorescence lifetime of the donor upon speciﬁc quenching with
the acceptor. The ﬂuorescence lifetime of the donor (sD) was
obtained by ﬁtting the intensity decay with a monoexponential ﬁt.
When cells were transfected with both EGFP-PDK1 and mRFP-PKB,
two distinct populations can be considered in ﬁrst approximation.
The ﬁrst one consists of the noninteracting EGFP-PDK1, with a
ﬂuorescence lifetime sD. The second consists of the interacting EGFP-
PDK1 with mRFP-PKB. The formation of the complex EGFP-PDK1/
mRFP-PKB leads to a transfer of energy from the donor to the
acceptor, inducing a decrease in the ﬂuorescence lifetime of EGFP-
PDK1. When measuring the ﬂuorescence intensity decay of EGFP-
PDK1 within the cell, photons from both interacting and non-
interacting EGFP-PDK1 were collected. Similarly, when transfected
with EGFP-PKB-mRFP, the conformational change of the fusion
protein leads to a variation of the FRET efﬁciency due to a variation
of distance between the two ﬂuorescent proteins. In both types of
experiments, the intensity decays should follow a multiexponential
law. However, biexponential ﬁts necessitate a high signal-to-noise
ratio. A minimum photon count of 1,000 at the maximum of the
intensity decay is required. Considering the limitations inherent to
experiments in cells, such as photobleaching and low concentration
of EGFP, the number of photons was insufﬁcient to accurately
proceed with a multiexponential analysis. Moreover, to accurately
identify the contribution of two lifetimes, it is preferable that they
differ by at least a factor of 2, which is generally not the case with
GFP-like ﬂuorescent proteins. Therefore, to detect FRET, we
measured the relative variation of lifetime obtained from mono-
exponential ﬁt [29]. In each experimental condition, a minimum of
ten cells were acquired and analysed. The experiments were repeated
at least three times for reproducibility. The intensity images were
converted to ﬂuorescence lifetime maps by ﬁtting the ﬂuorescence
intensity decay at each pixel. The ﬂuorescence lifetime was
represented in pseudo-colour with the same scale so that colours
were comparable in each experiment. Fluorescence lifetime distri-
butions were represented by histograms. The histograms were
normalised to the total number of pixels of the cell.
Statistical analysis. We used a nonparametric Mann-Whitney test
to compare the medians of the two data sets for the two-photon FLIM
data using GraphPad InStat software (version 3.0 for Mac-2001; http://
www.graphpad.com). To interpret the distribution of data, box and
whiskers plots were used. The box and whiskers plot is a histogram-
like method for displaying upper and lower quartiles, and maximum
and minimum values in addition to median [30].
An unpaired t-test with Welch correction was used for frequency
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interval) of variation in lifetime of GFP-PDK1 in the presence or not
of HA-PKB (Cyan 3 dye [Cy3]-HA antibody). Fifty-six or more cells
were analysed per experiment; the number of experiments were at
least ten.
Live imaging analysis. Enrichment in short lifetime pixels over
time was quantiﬁed from the lifetime histograms. The lifetime
histogram for each time point was normalised by the total number of
pixels Fi ¼ fi/N i, where fi and Ni are, respectively, the lifetime
histogram and the total number of pixels at time point t ¼ i. The
normalised histogram was subtracted from one of the ﬁrst images DFi
¼FI F0, where Fi and F0 are, respectively, the normalised histograms
at t ¼ i and t ¼ 0. The difference was integrated over s and the
enrichment in short lifetime pixels obtained by taking its maximum
gi¼Max
R
DFids. The enrichment gi was plotted as a function of time.
Cells were selected when translocation could be observed. Lifetime
measurements were acquired every 54 s. The enrichment in short
lifetime pixels was calculated as described above as a function of time.
Some cells presented transient periods during which no signiﬁcant
lifetime variation was measurable. For those cells, the enrichment in
short lifetime pixels was represented only after this transition period.
FRET by frequency domain FLIM. NIH3T3 cells were seeded at
30,000 on poly-L-lysine–coated glass coverslips in 24-well plates and
transfected as described above but with a maximum of 0.4 lg of DNA.
After treatment, the cells were washed twice in PBS and ﬁxed in 4%
paraformaldehyde (PFA) in PBS for 10 min. The cells were washed in
PBS and permeabilised with 0.2% Triton X-100 in PBS for 5 min
before being incubated with 1 mg/ml NaBH4 in PBS for 5 min.
Following another wash with PBS and 10-min incubation in the
blocking buffer PBS/1% BSA, the cells were incubated for 1 h with
0.22-lm ﬁltered anti-HA antibody labeled with Cy3 in the same
buffer. The coverslips were washed twice with PBS and once with
water and mounted on slides with the mounting medium Mowiol 4–
88 containing 2.5% (w/v) DABCO as an antifade. The slides were then
analysed in the frequency domain FLIM.
A detailed description of the FRET monitored by frequency
domain FLIM can be found elsewhere [31]. We have monitored
lifetime detection in the frequency (phase) domain. Phase methods
provide an average lifetime where sinusoidally modulated light is
used to excite the sample. The lag in the emitted ﬂuorescence signal
permits measurement of phase (sp) and modulation depth (sm) of the
ﬂuorescence. The lifetime, ,s., is the average of phase shift and
relative modulation depth (sm þ sp)/2 of the emitted ﬂuorescence
signal. We monitor the decrease in lifetime of donor (EGFP) in
presence of the acceptor (mRFP or Cy3 dye).
All images were taken using a Zeiss Plan-APOCHROMAT3100/1.4
numerical aperture, phase 3 oil objective, with images recorded at a
modulation frequency of 80.218 MHz. GFP-PDK1 was excited using
the 488-nm line of an argon/krypton laser, and the resultant
ﬂuorescence was separated using a combination of dichroic
beamsplitter (Q505 LP; Chroma Technology Corp.) and narrow band
emission ﬁlter (BP 514/10; Lys & Optik, Lyngby, Denmark).
Molecular modeling: Sequence homology building. For the PH
domain, we used the x-ray structure with Protein Data Bank (http://
www.rcsb.org/pdb) code 1UNP [7]. In this structure, only the two ﬁrst
amino acids were lacking and were not rebuilt (Figure 5). There is no
available structure for the kinase domain of human Akt-1 (PKBa), but
there are several structures for the homolog human Akt-2 kinase
domain (PKBb). Among them, one of the most complete is 1GZN with
a resolution of 2.5 A ˚ [11]. In this side chain, the following amino acids
are lacking: 146–147, 198–206, 253, 296, and 442. These were rebuilt
prior to any experiment using the Homology module of Insight II
(Accelrys, http://www.accelrys.com). Because the two proteins (Akt-1
and Akt-2) have a very high homology rate (98.8% with 82.3% of
strict identity), building a model from this homology sequence was
straightforward. Moreover, in the chosen alignment (Figure 5), there
is a difference of only one amino acid between the two sequences that
results from a two–amino acid deletion after position 114 and a one–
amino acid insertion at position 268 (Figure 5, arrows). Alignment of
sequences was performed using the Homology multiple-sequence
aligner software via the PAM (120 or 250) matrices or the ClustalW
software (http://www.ebi.ac.uk/clustalw) as implemented within Ho-
mology module. In these latter cases, alignments were performed
using the Blosum and Gonnet matrices. The crude model of each
domain, after full protonation at pH 7.4, was reﬁned by several cycles
of splice repairs on the loops and relaxation on the SCR’s side by 100
steps of Steepest Descent and 500 cycles of conjugate gradient. Small
5-ps molecular dynamics runs were performed on each loop in order
to relax the strains. Finally, the entire backbone was ﬁxed and the side
chains were fully minimised with conjugate gradient method until a
root-mean-square of 0.1 kcal/A ˚ /mol was obtained. The minimisation
process was resumed by applying a tethering constraint to the
backbone. This constraint was slowly lowered (starting with a 100
kcal/A ˚ /mol) force constant) in a stepwise manner so that at each step
the energy of the root-mean-square gradient was less than 0.1 0.1 kcal/
A ˚ /mol (steps are 100, 50, 25, 10, and 0 0.1 kcal/A ˚ /mol).
Molecular modeling: Potential maps calculations. Lipophilicity
potentials were calculated using a previously described software [32]
that calculated on each node of a 1-A ˚ cubic grid the sum of the
lipophilicity contribution of each nonhydrogen atom as a function of
Figure 5. Sequence Alignment between Akt-1 and Akt-2 Kinase Domain
doi:10.1371/journal.pbio.0050095.g005
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potential is located on the same side as the ATP active site with the
following amino acids: Leu316, Leu321, Lys356 (alkyl chain only),
Phe358, Leu362, and Met363. For the PH domain, four small
hydrophobic patches are also located on the same side of the protein
and on a ‘‘plateau’’ with the following amino acids: Val4, Tyr18, Ile19,
Leu52, and Trp80.
The Molecular Electrostatic Potential (MEP) maps were drawn
within the software PYMOL (version 0.97) after calculations
performed using the implemented APBS plug-in. This last package
enabled us to efﬁciently evaluate electrostatic properties by solving
the Poisson-Boltzmann equation [33].
All possible hydrophobic and electrostatic interactions were
properly ﬁtted. The Trp80 at the extremity of a loop inserts precisely
inside a deep cleft in the kinase domain with Lys297, Glu298, and
Glu314 located around it. Moreover, in this conﬁguration, the C
terminus of the PH domain is on the same side as the N terminus of
the kinase domain. In this model, the PH domain completely blocks
the entry of the ATP active site and Thr308 will not be accessible.
Supporting Information
Figure S1. PKB–PDK1 Interaction Monitored by Frequency Domain
FLIM
(A) Fluorescence frequency domain FLIM images of NIH3T3 cells
transfected with GFP-PDK1 alone or GFP-PDK1 together with HA-
PKB as indicated. The top panels represent intensity images of the
donor fusion construct GFP-PDK1. The middle panels show of the
use of an epiﬂuorescence OCRA camera in addition to frequency
FLIM images to provide a better quality image of the FRET partners
(donor in green and acceptor in yellow). The bottom panels represent
the calculated average lifetime maps of GFP-PDK1 alone or in
presence of the acceptor HA-PKB recognized with Cy3-labeled anti-
HA antibody after ﬁxation. The lifetimes are shown in a pseudo-
colour scale ranging from 1.7 to 2.1 ns.
(B) The two-dimensional diagram presents the statistical analysis of
the lifetimes phase (sp) and modulation (sm) of cells taken from at
least ten different experiments (n being the total number of cells
acquired). The diagonal shift toward the lower lifetimes indicates the
occurrence of FRET. The conditions are GFP-PDK1 alone (black
circle), GFP-PDK1 in presence of PDGF (black square), GFP-PDK1
with Cy3-HA-PKB (white circle), and GFP-PDK1 with Cy3-HA-PKB
upon 5-min PDGF treatment (red circle). For the statistics, an
unpaired t-test with Welsh correction was used. An extremely
signiﬁcant p-value (p , 0.0001) was obtained at 95% conﬁdence
interval by comparing nonstimulated GFP-PDK1þCy3-HA-PKB cells
(white circle) with GFP-PDK1 cells stimulated with PDGF (black
square). An extremely signiﬁcant p-value (p , 0.0001) was also
obtained when comparing PDGF-stimulated GFP-PDK1 cells cotrans-
fected with Cy3-HA-PKB (red circle) versus nonstimulated cells
(white circle). The difference between GFP-PDK1 nonstimulated cells
(black circle) and PDGF-stimulated cells (black square) was not
signiﬁcant (p ¼ 0.10).
Found at doi:10.1371/journal.pbio.0050095.sg001 (9.9 MB EPS).
Figure S2. Regulation of PKB Phosphorylation in the Cytoplasm by Its
PH Domain and Phosphatases
(A) NIH3T3 cells expressing RFP-PKB were stimulated with PDGF as
indicated or treated for increasing periods of time with 1 lM okadaic
acid alone. The phosphorylation of RFP-PKB on Thr308 and Ser473
was determined with phosphospeciﬁc antibodies, and the expression
by Western blot with an anti-PKB antibody (pan Akt). The lower
panel represents Thr308 phosphorylation of endogenous PKB in the
same experiment. The quantiﬁcation of the bands was performed by
densitometry. Ser473 is shown in black bars, and Thr308 is shown in
gray bars. The phospho bands were normalised to total protein.
(B) The same experiment as in (A) was performed but with NIH3T3
cells expressing RFP-PKB R25C.
(C) The same experiment as in (A) was performed but with NIH3T3
cells expressing RFP-DPH PKB. Similar levels of Thr308 phosphor-
ylation of endogenous PKB in (A), (B), and (C) allow a direct
comparison between the level of Thr308 phosphorylation of
exogenous RFP-PKB or mutants shown in the middle panels of (A),
(B), and (C).
(D) NIH3T3 cells were transfected with RFP-PKB or RFP-DPH PKB
alone or together with GFP-PDK1 (WT) or PH domain defective GFP-
PDK1 RRR. The phosphorylation of RFP-PKB and RFP-DPH PKB on
Thr308 was determined with a phosphospeciﬁc antibody, and the
expression by Western blotting with an anti-PKB antibody (pan Akt).
Levels of expression of GFP-PDK1 and GFP-PDK1 RRR in the bottom
panel were determined with an anti-GFP antibody.
(E) NIH3T3 cells expressing RFP-PKB were pretreated for 20 min
with LY294002 as indicated and stimulated with PDGF for 5 min. The
expression of RFP-PKB was determined by Western blot with an anti-
HA antibody, and the phosphorylation of Thr308 and Ser473 were
detected by phosphospeciﬁc antibodies. The bottom panel represents
the Ser473 phosphorylation of endogenous PKB.
Found at doi:10.1371/journal.pbio.0050095.sg002 (5.6 MB EPS).
Figure S3. Effect of PH Domain Mutagenesis on PKB–PDK1 Docking
(A) NIH3T3 cells were transfected either with GFP-PDK1 RRR alone
or together with RFP-PKB as indicated. Upon 5 min PDGF
stimulation, PH domain defective mutant GFP-PDK1 RRR did not
translocate to the plasma membrane (the two-photon images of the
donor). The lifetimes are presented in pseudo-colour scale ranging
from 2.30 to 2.70 ns.
(B) The same experiment as in (A) but with GFP-PDK1 alone or
cotransfected with RFP-PKB R25C was performed. Upon PDGF
stimulation, PH domain defective RFP-PKB R25C did not translocate
to the plasma membrane.
(C) The statistical analysis for experiments (A) and (B) is shown as box
and whiskers plots. For both mutants, FRET efﬁciencies do not vary
upon stimulation (p ¼ 0.2).
Found at doi:10.1371/journal.pbio.0050095.sg003 (966 KB EPS).
Figure S4. Effect of Mutations on PKB–PDK1 Docking
(A and B) GFP-tagged mutants of PDK1 PIF pocket (L155E) (A) and
the phosphate-binding pocket (R131A) (B) were coexpressed with
RFP-PKB.
(C) RFP-PKB AA, which cannot be phosphorylated on Thr308 and
Ser473, was coexpressed with GFP-PDK1. Upon 5 min PDGF
stimulation, GFP-PDK1 and RFP-PKB mutant constructs translocated
to the plasma membrane in the same manner as the wild-type (wt)
constructs (see Figure 1). The graph represents the distributions of
the lifetimes of the cells under the following conditions: GFP-PDK1
wt or mutants alone (blue line) or GFP-PDK1 wt or mutant
cotransfected with RFP-PKB wt or mutant prior (green line) or upon
PDGF stimulation (orange line). The contribution of the pixels at the
plasma membrane and cytoplasm are represented in red and light
green, respectively.
(D) Statistical analysis of the FRET efﬁciencies is shown as box and
whiskers plots. These mutations do not affect the interaction
compared to the wt constructs.
Found at doi:10.1371/journal.pbio.0050095.sg004 (1.6 MB EPS).
Figure S5. Model for GFP and RFP Change in Distance upon GFP-
PKB-RFP Change in Conformation
(A) The kinase domain of PKB is shown in yellow ribbons with GFP
and RFP in green and red ribbons, respectively. In cyan, PKB PH
domain is shown in its ‘‘PH-in’’ conformation. The white dashed
lines represent the linkages between the PKB domains and GFP or
RFP.
(B) When PH domain moves to its ‘‘PH-out’’ conformation (dark
blue), GFP moves to a new location. During this movement, the
distance between GFP and RFP is roughly halved (distances shown in
white lines are taken between the centres of domains or proteins).
Found at doi:10.1371/journal.pbio.0050095.sg005 (1.6 MB EPS).
Figure S6. Cotranslocation of RFP-PKB with GFP-PDK1 Shown by
Confocal Imaging
NIH3T3 cells were transfected with GFP-PDK1 and RFP-PKB. The
cells were stimulated with PDGF for 5 min as indicated and ﬁxed.
Confocal images of the GFP-PDK1 and RFP-PKB were taken at mid-
section using a Zeiss laser scanning confocal microscope (LSM 510),
argon 458/488 laser with a 363 oil Apochromat objective. A merge
image was created to visualise in yellow the colocalisation of the two
constructs at the plasma membrane upon PDGF stimulation.
Found at doi:10.1371/journal.pbio.0050095.sg006 (2.8 MB EPS).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the genes and gene products discussed in this paper are
mRFP (AF_506027), murine AKT1 (NM_009652), and construct
pCMV5-EGFP-PDK1 (human PDK1, AF_017995). The Swiss-Prot
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In Vivo PKB Molecular Mechanism(http://www.ebi.ac.uk/swissprot) database code for the homolog
human Akt-2 kinase domain (PKBb) is P31751.
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